go-v.orgdoi

Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not

Young‐Hoon Jeong, Soon Auck Hong, Hye Shin Ahn, Soo Kyung Ahn, Min Kyoon Kim · Journal of Cancer · 2021

  • DOI 10.7150/jca.59419
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Background: Accurate determination of human epidermal growth factor receptor 2 (HER2) status on breast core needle biopsy (CNB) tissue is important for determining neoadjuvant chemotherapies (NACs) for primary breast cancer.However, HER2 discrepancies occur before and after surgery, creating difficulties in the administration of appropriate NAC.This study aimed to identify the clinical factors affecting these discrepancies.Methods: This study was conducted on patients with primary breast cancer who underwent breast surgery from January 2012 to December 2018 at the Chung-Ang University Hospital.HER2 status was analyzed using immunohistochemistry.

HER2 was graded as 0 to +3, and all 2+ cases were evaluated for gene amplification.The patients were divided into two groups based on whether or not they received chemotherapy.Patient and clinical characteristics between the two groups were compared using the χ2 test and a logistic regression model.Results: A total of 443 patients were evaluated; 384 patients (86.7%) did not receive NAC, and 59 patients (13.3%) received NAC.The HER2 discordance rate was 12.5% in the no NAC group and 23.7% in the NAC group.Most cases showed a change in HER2 status from negative in CNB to positive in surgical biopsy (SB).Clinicopathological factors affecting HER2 change in the no NAC group were larger tumor size and higher histologic grade.Meanwhile, poor response to prior chemotherapy affected HER2 change in NAC.Conclusion: The overall accuracy of CNB in determining HER2 status was lower in the NAC group than in the no NAC group.Some clinicopathological factors may affect HER2 changes in each group at different levels.Based on the HER2 status at the time of diagnosis, the choice of HER2-targeted therapy may vary, even if this is not true.Future research on the effects of changes in HER2 status between CNB and SB on prognosis is needed.

Open the resolved locator · 10.7150/jca.59419

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:53 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p4722.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.